When was Organoid Sciences founded?

Organoid Sciences was founded in 2019 and raised its 1st funding round 1 year after it was founded.

Where is Organoid Sciences located?

Organoid Sciences is headquartered in Seongnam-si, South Korea.

Who is the current CEO of Organoid Sciences?

Jongman Yoo of Organoid Sciences.

How many employees does Organoid Sciences have?

As of Aug 31, 2026, the latest employee count at Organoid Sciences is 54.

Is Organoid Sciences a funded company?

Organoid Sciences is a funded company, having raised a total of $39M across 2 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Mar 25, 2020.

When was the latest funding round of Organoid Sciences?

Organoid Sciences' latest funding was a $***** Series B round on Jan 13, 2022, with participation from 10 investors. Its primary sector is Regenerative Medicine. In South Korea, the Regenerative Medicine sector has seen $44.2M in funding in 2026 to date.

Where does Organoid Sciences rank among its competitors?

Organoid Sciences ranks 17th amongst 69 active competitors, of which 18 are funded. It stands 4th in terms of total funding among its competitors. The most recent competitor to raise funding was BioStem Technologies, which secured $2.5M in May, 2026.

Who are the top competitors of Organoid Sciences?

Organoid Sciences' top competitors include Pandorum, Stellular Bio and Orthofix. Among them, BioStem Technologies secured the most recent funding round in May, 2026.

Organoid Sciences - 2026 Company Profile, Team, Funding & Competitors

Organoid Sciences is a public company based in Seongnam-si (South Korea), founded in 2019. It operates as a Developer of regenerative medicines for multiple diseases. Organoid Sciences has raised $39M in funding from investors like Aju IB Investment, Korea Development Bank Europe and Dongwha Pharm. The company has 69 active competitors, including 18 funded and 14 that have exited. Its top competitors include companies like Pandorum, Stellular Bio and Orthofix.

Company Details

Organoid Sciences is a developer of regenerative medicines for multiple diseases. It uses cannabinoid-based technology for the development of a regenerative medicine pipeline.

Website: organoidrx.com
Email ID: *****@organoidrx.com
Phone Number: +82 **********

Key Metrics

Founded Year

2019

Location

Seongnam-si, South Korea

Stage

Public

Total Funding

$39M in 2 rounds

Latest Funding Round

Series B, Jan 13, 2022, $*****

Investors

Aju IB Investment & 10 more

Ranked

17^th among 69 active competitors

Employee Count

54 as on Aug 31, 2026

Similar Companies

Pandorum & 84 more

Exit Details

Public

View Organoid Sciences' full profile

Organoid Sciences got listed on May 09, 2025.

Click here to take a look at Organoid Sciences's IPO in detail

Organoid Sciences has raised a total funding of $39M over 2 rounds. Its first funding round was on Mar 25, 2020. Its latest funding round was a Series B round on Jan 13, 2022 for $*****. 10 investors participated in its latest round. Organoid Sciences has 11 institutional investors.

Here is the list of recent funding rounds of Organoid Sciences:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 13, 2022	2471305	Series B	5770582	7112942	8387770	2172218
Mar 25, 2020	7485279	Series A	1973308	1967219	Aju IB Investment	Company K Partners & 2 more

Access funding benchmarks and valuations. Sign up today!

View details of Organoid Sciences's funding rounds and investors

Organoid Sciences' employee count trend

Organoid Sciences has 54 employees as of Aug 26. Here is Organoid Sciences's employee count trend over the years:

Employee count trend for Organoid Sciences

Uncover Organoid Sciences' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Organoid Sciences include Pandorum, Stellular Bio and Orthofix. Here is the list of Top 10 competitors of Organoid Sciences, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Pandorum 2011, Bengaluru (India), Series B	Developer of regenerative medicine and 3D tissues	$52.1M	Indian Angel Network, BTB Venture & 89 others	65/100
2nd	Stellular Bio 2014, Watertown (United States), Series A	Developer of a platform for producing allogeneic, stem-cell-derived platelet-like cells	$37.5M	Qiming, Vivo Capital & 5 others	59/100
3rd	Orthofix 1980, Lewisville (United States), Public	Developer of reconstructive and regenerative solutions for bone-related conditions	-	-	59/100
4th	Avita Medical 1992, Cambridge (United Kingdom), Public	Regenerative and Respiratory Medicine product company	-	BioScience Managers, Oceania Capital Partners ... & 6 others	59/100
5th	TreeFrog Therapeutics 2018, Talence (France), Series B	Developer of stem cells and organoids using proprietary technology	$84.2M	XAnge, Leonard Green and Partners & 12 others	59/100
6th	Organogenesis 1985, Canton (United States), Public	Regenerative tissue innovations for advanced wound care and surgical solutions	$30M	Spring St. Group, Eastward Capital Partners ... & 2 others	59/100
7th	Ensoma 2019, Boston (United States), Series B	Developer of in vivo hematopoietic stem cell engineering for genomic medicine	$205M	5AM Ventures, Arix Bioscience & 18 others	58/100
8th	ROKIT Healthcare 2012, Seoul (South Korea), Public	Provider of 4D bio-printer solutions for tissue regenerative	$30M	DRADS Capital, Korean Development Bank & 16 others	54/100
9th	TikoMed 2002, Viken (Sweden), Public	Developers of regenerative medicine for cell therapies	$14.7M	-	52/100
10th	BioStem Technologies 2006, Pompano Beach (United States), Public	Provider of placental-based amniotic tissue products	-	-	51/100
17th	Organoid Sciences 2019, Seongnam-si (South Korea), Public	Developer of regenerative medicines for multiple diseases	$39M	Korea Development Bank Europe, Asan Foundation ... & 9 others	44/100